SCHEMBL24323341

SCHEMBL24323341

CC(C)(C)OCN(C(=O)OC(C)(C)C)c1nc(Cl)cc(Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.38
STK17A Q9UEE5 1/20 0.38
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
LMNA P02545 2/20 0.32
KMT2A Q03164 2/20 0.32
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31
GLA P06280 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
XBP1 P17861 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HSD17B10 Q99714 1/20 0.31
RXRA P19793 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26674946 0.85 RXRA (0.34) STK17BSTK17AACACBACACALMNA
SCHEMBL18167877 0.79 STK17B (0.37) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL22509297 0.77 PAX8 (0.39) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL22502038 0.75 STK17B (0.35) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL29059429 0.74 CYP1A2 (0.41) ACACBACACAALDH1A1HSD17B10F2
SCHEMBL8819965 0.71 SYK (0.35) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL4439238 0.71 SMN1; SMN2 (0.36) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL24299010 0.70 LMNA (0.34) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL4555591 0.70 TAS1R3 (0.39) STK17BSTK17AACACBACACAHSP90AA1
SCHEMBL1053992 0.69 HSP90AA1 (0.36) STK17BSTK17AACACBACACAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382925-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-30 US disclosed
WO-2022076622-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382925-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B STK17B 2376/4885STK17A 1837/4885ACACB 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.